PMID- 14982868
OWN - NLM
STAT- MEDLINE
DCOM- 20040708
LR  - 20210206
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 103
IP  - 11
DP  - 2004 Jun 1
TI  - Deletion of chromosome band 13q14 as detected by fluorescence in situ 
      hybridization is a prognostic factor in patients with multiple myeloma who are 
      receiving allogeneic dose-reduced stem cell transplantation.
PG  - 4056-61
AB  - We investigated in a retrospective multicenter study the impact of chromosome arm 
      13q deletion (13q-) as detected by fluorescence in situ hybridization (FISH) on 
      outcome after dose-reduced allografting in patients with multiple myeloma. In 68 
      of 140 patients, data on chromosome 13q status were available. Most patients 
      included had advanced myeloma. At 2 years, patients with 13q deletion (n = 31) 
      had a shorter event-free (18% vs 42%; P =.05) and overall survival (18% vs 67%; P 
      =.03) than patients without 13q- (n = 37). Patients with 13q- experienced a 
      higher relapse rate (77% vs 44%; P <.001) but a similar incidence of 
      transplantation-related mortality at one year (24% vs 18%). In a multivariate 
      analysis, 13q- remained a significant risk factor for a higher relapse rate 
      (hazard ratio [HR], 3.28; 95% confidence interval [CI], 1.31-8.24; P =.01) and a 
      shorter event-free survival (HR, 1.94; 95% CI, 1.03-3.67; P =.04). Concerning 
      overall survival, 2 or more cycles of prior high-dose chemotherapy were 
      associated with a significantly higher probability of death (HR, 2.48; 95% CI, 
      1.19-5.17; P =.02), while patients with deletion 13q had a nearly 2 times higher 
      risk of death (HR, 1.94; 95% CI, 0.95-3.98; P =.07) after dose-reduced allogeneic 
      stem cell transplantation.
FAU - Kroger, Nicolaus
AU  - Kroger N
AD  - Department of Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, 
      Martinistrasse 52, D-20246 Hamburg, Germany. nkroeger@uke.uni-hamburg.de
FAU - Schilling, Georgia
AU  - Schilling G
FAU - Einsele, Hermann
AU  - Einsele H
FAU - Liebisch, Peter
AU  - Liebisch P
FAU - Shimoni, Avichai
AU  - Shimoni A
FAU - Nagler, Arnon
AU  - Nagler A
FAU - Perez-Simon, Jose A
AU  - Perez-Simon JA
FAU - San Miguel, Jesus F
AU  - San Miguel JF
FAU - Kiehl, Michael
AU  - Kiehl M
FAU - Fauser, Axel
AU  - Fauser A
FAU - Schwerdtfeger, Rainer
AU  - Schwerdtfeger R
FAU - Wandt, Hannes
AU  - Wandt H
FAU - Sayer, Herbert G
AU  - Sayer HG
FAU - Myint, Han
AU  - Myint H
FAU - Klingemann, Hans
AU  - Klingemann H
FAU - Zabelina, Tatjana
AU  - Zabelina T
FAU - Dierlamm, Judith
AU  - Dierlamm J
FAU - Hinke, Axel
AU  - Hinke A
FAU - Zander, Axel R
AU  - Zander AR
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20040224
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 13
MH  - Disease-Free Survival
MH  - Female
MH  - Graft vs Host Disease/mortality
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*genetics/mortality/*therapy
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Recurrence
MH  - Remission Induction
MH  - Risk Factors
MH  - Survival Analysis
MH  - Transplantation Chimera
EDAT- 2004/02/26 05:00
MHDA- 2004/07/09 05:00
CRDT- 2004/02/26 05:00
PHST- 2004/02/26 05:00 [pubmed]
PHST- 2004/07/09 05:00 [medline]
PHST- 2004/02/26 05:00 [entrez]
AID - S0006-4971(20)55396-2 [pii]
AID - 10.1182/blood-2003-12-4435 [doi]
PST - ppublish
SO  - Blood. 2004 Jun 1;103(11):4056-61. doi: 10.1182/blood-2003-12-4435. Epub 2004 Feb 
      24.